Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Blood (2016) 127 (9): 1117–1127.

https://doi.org/10.1182/blood-2015-11-679134

Published: 2016

Includes: Supplemental data

Journal Articles

Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry

Jeffrey A. Boyd, MBA, Bruce L. Levine, PhD, Kathrin Jinivizian, BS, Margit A. Jeschke, PhD, Megan M. Suhoski Davis, PhD, Zhaohui Zheng, MS, Daniel Stark, PhD, Liza Loidolt, MS, MBA, Christopher H. Keir, MD MS, Patricia A. Wood, MD PhD

Blood (2015) 126 (23): 3100.

https://doi.org/10.1182/blood.V126.23.3100.3100

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2015) 126 (23): 183.

https://doi.org/10.1182/blood.V126.23.183.183

Published: 2015

Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Blood (2014) 124 (21): 3087.

https://doi.org/10.1182/blood.V124.21.3087.3087

Published: 2014

Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Blood (2014) 124 (21): 1982.

https://doi.org/10.1182/blood.V124.21.1982.1982

Published: 2014

Journal Articles

Adoptive Immunotherapy With Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy In Patients With Chronic Lymphocytic Leukemia

Stephen J. Schuster, MD, Chitra M. Hosing, MD, Elizabeth J Shpall, MD, Bruce L. Levine, PhD, Nicole A. Aqui, MD, Elise A. Chong, MD, Jakub Svoboda, MD, Doyle Bosque, ADN, Julio Cotte, Zhaohui Zheng, Indreshpal Kaur, PhD, Elizabeth Veloso, JD, BSN, Catherine M. Bollard, MBChB, MD, Michael J. Keating, MD, Carl H. June, MD

Blood (2013) 122 (21): 2874.

https://doi.org/10.1182/blood.V122.21.2874.2874

Published: 2013

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemison, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 4162.

https://doi.org/10.1182/blood.V122.21.4162.4162

Published: 2013

Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 873.

https://doi.org/10.1182/blood.V122.21.873.873

Published: 2013

Journal Articles

Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19

Michael Kalos, PhD, Farzana Nazimuddin, Jeffrey M. Finklestein, Minnal Gupta, Irina Kulikovskaya, David E. Ambrose, Saar Gill, MD, PhD, Simon F. Lacey, PhD, BSc, Zhaohui Zheng, J. Joseph. Melenhorst, PhD, Bruce L. Levine, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, David L. Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 163.

https://doi.org/10.1182/blood.V122.21.163.163

Published: 2013

Journal Articles

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

Blood (2013) 121 (9): 1524–1533.

https://doi.org/10.1182/blood-2012-07-447250

Published: 2013

Includes: Supplemental data

Journal Articles

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

Blood (2012) 120 (21): 352.

https://doi.org/10.1182/blood.V120.21.352.352

Published: 2012

Journal Articles

Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

Blood (2012) 120 (21): 472.

https://doi.org/10.1182/blood.V120.21.472.472

Published: 2012

Journal Articles

Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1

Blood (2012) 120 (21): 755.

https://doi.org/10.1182/blood.V120.21.755.755

Published: 2012

Journal Articles

Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up

Stephen J. Schuster, MD, Nicole A. Aqui, MD, Benjamin Musher, MD, Bruce L. Levine, PhD, Charalambos Andreadis, MD, MS, Elise A. Chong, BA, Sunita D. Nasta, MD, Amanda Gordon, CRNP, Julio Cotte, Zhaohui Zheng, MA, Andrea L. Brennan, Elizabeth Veloso, JD, BSN, Carl H. June, MD

Blood (2012) 120 (21): 1631.

https://doi.org/10.1182/blood.V120.21.1631.1631

Published: 2012

Journal Articles

Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia

Blood (2011) 118 (21): 2855.

https://doi.org/10.1182/blood.V118.21.2855.2855

Published: 2011

Journal Articles

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Blood (2011) 117 (3): 788–797.

https://doi.org/10.1182/blood-2010-08-299396

Published: 2011

Includes: Supplemental data

Journal Articles

Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Stephen J. Schuster, MD, Bruce L. Levine, PhD, Sunita Nasta, MD, Charalambos Andreadis, MD, Anthony R. Mato, MD, Nicole Aqui, MD, Julio Cotte, Zhaohui Zheng, MS, Andrea Cannon, Benjamin Musher, MD, Bridget Fonash, RN, BSN, Lisa H. Downs, CRNP, Elizabeth Veloso, RN, JD, Carl H. June, MD

Blood (2007) 110 (11): 126.

https://doi.org/10.1182/blood.V110.11.126.126

Published: 2007

Journal Articles

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Charalambos Andreadis, Bruce L. Levine, Sunita D. Nasta, Julio Cotte, Zhaohui Zheng, Andrea Cannon, Kathleen Wiley, Lisa H. Downs, Bernadette Diccion, Elizabeth Veloso, Carl H. June, Stephen J. Schuster

Blood (2006) 108 (11): 2717.

https://doi.org/10.1182/blood.V108.11.2717.2717

Published: 2006

Journal Articles

Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Charalambos Andreadis, Bruce L. Levine, Julio Cotte, Zhaohui Zheng, Rebecca Mair, Andrea Cannon, Jason Harrow, Marcy Traum, Elise A. Chong, Lisa H. Downs, Dan T. Vogl, Jakub Svoboda, Carl H. June, Stephen J. Schuster

Blood (2005) 106 (11): 1505.

https://doi.org/10.1182/blood.V106.11.1505.1505

Published: 2005

NARROW

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Adoptive Immunotherapy With Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy In Patients With Chronic Lymphocytic Leukemia

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1

Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up

Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only